2) communicating with all Specialty Pharmacies (SPs), Closed Door Pharmacies (CDPs) - including Genoa, and Patient-Physician Services (HUB partner) in support of Neurocrine Biosciences marketed products in the U.S. 3) building and upholding the integrity of Neurocrine Biosciences pharmacy distribution network by conducting all vetting activities within an assigned geography, including communication of approval, and denial or any subsequent removal from the network. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis and uterine fibroids , as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas.